Request Sample

Global Diabetes Drugs Market

Dec. 1, 2019

Global Diabetes Drugs Market, By Diabetes Type (Type-1 & Type-2), By Drug (Oral Anti-Diabetic Drugs (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylurea, and Meglitinides), Insulins (Basal or Long-acting Insulin, Bolus or Fast-acting Insulin, Traditional Human Insulin, and Biosimilar Insulin), Non-insulin Injectable drugs (GLP-1 Receptor Agonists and Amylin Analogue), Combination Drugs (Combination Insulin and Oral Combination)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Latin America, Europe, Asia-Pacific, and Middle East and Africa) - Global Forecast, 2020-2025.

Report Code :FMR291      
Pages :210 Pages
Format :   PPT Format   PDF Format

The global diabetes drugs market was valued at US$ xx million in the year 2019. This market is estimated to be valued at US$ xx million in the year 2020 and is expected to reach US$ xx million by the year 2025, with an estimated CAGR of 3.8% during the forecast period (2020-2025). The global market for diabetes drugs is driven largely by an increasing number of diabetic populations. According to the International Diabetes Federation, 463 million adults were estimated to suffer from diabetes in 2019. Additionally, the growth of the diabetes drug market is mainly due to the growth of the obese population, increased healthcare spending and strong government encouragement. Thiazolidinediones, Metformin, Meglitinides, Sulfonylureas, and Dipeptidyl peptidase-4 (DPP-4) inhibitors are some of the drugs used for the treatment of diabetes.

Table 1. Global Diabetes Drugs Market Synopsis

Parameters

Description

Market Value (US$ Mn) for the Period

2018-2025

Base Year

2019

Forecast Period

2020-2025

Market Segmentation (By Diabetes Type)

Type-1 & Type-2

Market Segmentation (By Drug)

Oral Anti-Diabetic Drugs (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylurea, and Meglitinides), Insulins (Basal or Long-acting Insulin, Bolus or Fast-acting Insulin, Traditional Human Insulin, and Biosimilar Insulin), Non-insulin Injectable drugs (GLP-1 Receptor Agonists and Amylin Analogue), Combination Drugs (Combination Insulin and Oral Combination)

Market Segmentation (By Distribution Channel)

Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regions Covered

North America, Latin America, Europe, Asia-Pacific, Middle East & Africa,

Key Players Coverage

Daiichi Sankyo, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Abbott, AstraZeneca, Biocon, Sun pharma, Sanofi, Novartis, Merck & Co., Pfizer, Akros Pharma, Amgen, Adocia, Peptron, Takeda, among others

Key Insights

  • Latest Updates
  • Analyst Views
  • Future Outlook of the Market

 

Market Dynamics

Diabetes is a disorder that involves an abnormally elevated insulin concentration in the blood. Diabetes Drugs are used by lowering blood glucose levels to treat diabetes mellitus. Additionally, the high consumption of unhealthy junk foods, and smoking is poised to increase the incidence of diabetes patients, and hence increasing the demand for diabetes drugs. For instance, according to Centers for Disease Control and Prevention (CDC), smoking increases the possibility of diabetes; smokers are 30–40% more likely to develop type 2 diabetes than nonsmokers. For instance, in September 2019, the FDA approved Rybelsus (semaglutide) oral tablets to improve the level of blood sugar in adult patients with type 2 diabetes. However,, various product recalls may impede the market growth during the forecast period. For instance, in March 2020, JAMP Pharma Corporation voluntarily recalled Metformin, an anti-diabetic medication, from the Canadian market, owing to potential presence of nitrosamine impurities in the finished product.

Figure 1. Diabetes Drugs Market Scenario Forecast (Likely, Conservative, and Optimistic Scenario), 2019 and 2025 (US$ Mn)

Note: The above figure is shown for illustrative purposes only, the actual data may vary and will be incorporated in the report.

The market for North America is expected to have the largest market share during the forecast period. In 2016, 9.6% of the adult population of America suffered from diabetes, according to the WHO. Additionally, growing millions of obese individuals, changing habits and rising healthcare spending have fueled the growth of America's diabetes drug market. Rising cholesterol levels and smoking raise the risk of developing diabetes. 95 million adults in the U.S. had diagnosed high cholesterol (>240 mg/dl) levels, according to the Centers for Disease Control and Prevention (2017).

Europe represents the second-largest market for diabetes drugs due to the availability of research funds, and government support for research & development. For instance, in Europe the research project named “Sport & Diabetes” co-founded by the Erasmus+ programme of the European Union started in April 2020. This research project aims to address the concerns of sport-persons  suffering from diabetes.

Figure 2. Regional Analysis

 

Note: Above figure is shown for illustrative purposes only, the actual data may vary and will be incorporated in the report.

Competitive Landscape

Key players in global diabetes drugs market include Daiichi Sankyo, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Glenmark, Abbott, AstraZeneca,  Sun Pharma, Sanofi, Novartis, Merck & Co., Pfizer, Akros Pharma,  Adocia, Peptron, Takeda, among others. Key players in the market are focused on launching new products in varied geographies and are involved in new partnerships for efficient research and development of novel diabetes drugs. For instance, in April 2019, Glenmark introduced novel antibiotic drug Remogliflozin in India. Remogliflozin is an SGLT2 inhibitor used for treating diabetes mellitus.

Figure 3. Market Share of Key Players, 2019

 

Note: Above figure is shown for illustrative purposes only, the actual data may vary and will be incorporated in the report.

By Diabetes Type

  • Type-1
  • Type-2

By Drug

  • Oral Anti-Diabetic Drugs
    • Biguanides
      • Metformin
    • Alpha-Glucosidase Inhibitors
    • Dopamine D2 Receptor Agonist
      • Cycloset (Bromocriptin)
    • Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors
      • Invokana (Canagliflozin)
      • Jardiance (Empagliflozin)
      • Farxiga/Forxiga (Dapagliflozin)
      • Suglat (Ipragliflozin)
    • Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
      • Januvia (Sitagliptin)
      • Onglyza (Saxagliptin)
      • Tradjenta (Linagliptin)
      • Vipidia/Nesina (Alogliptin)
      • Galvus (Vildagliptin)
    • Sulfonylureas
    • Meglitinides
  • Insulins
    • Basal or Long-acting Insulin
      • Lantus (Insulin Glargine)
      • Levemir (Insulin Detemir)
      • Toujeo (Insulin Glargine)
      • Tresiba (Insulin Degludec)
      • Basaglar (Insulin Glargine)
    • Bolus or Fast-acting Insulin
      • NovoRapid/Novolog (Insulin Aspart)
      • Humalog (Insulin Lispro)
      • Apidra (Insulin Glulisine)
    • Traditional Human Insulin
      • Novolin/Actrapid/Insulatard
      • Humulin
      • Insuman
    • Biosimilar Insulin
      • Insulin Glargine Biosimilars
      • Human Insulin Biosimilars
  • Non-insulin Injectable drugs
    • GLP-1 Receptor Agonists
      • Victoza (Liraglutide)
      • Byetta (Exenatide)
      • Bydureon (Exenatide)
      • Trulicity (Dulaglutide)
      • Lyxumia (Lixisenatide)
    • Amylin Analogue
      • Symlin (Pramlintide)
  • Combination Drugs
    • Combination Insulin
      • NovoMix (Biphasic Insulin Aspart)
      • Ryzodeg (Insulin Degludec and Insulin Aspart)
      • Xultophy (Insulin Degludec and Liraglutide)
    • Oral Combination
      • Janumet (Sitagliptin and Metformin HCl)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa
rm
Kindly fill the below form and we will contact you within 24 hours
I have read and accept Privacy Policy

Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Note: This report provides an in-depth analysis of the global diabetes drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020-2025), considering 2019, as the base year.

  • What are the trends adopted by key players in the global diabetes drugs market?
  • What key factors are expected to increase the demand for the diabetes drugs market during the forecast period 2020-2025?
  • What are the major challenges inhibiting the growth of the global diabetes drugs market?
  • Which drug is expected to dominate the global diabetes drugs market in the coming years?
  • What is the total market value (US$ Mn) generated in the global diabetes drugs market by diabetes type in 2019 and what are the forecasts by 2025?
  • Which distribution channel is expected to dominate the diabetes drugs market in the coming years?
  • What was the total revenue generated by the global diabetes drugs market across different regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) in 2019, along with CAGR (%) for the period (2020-2025)?
  • Who are the key players contributing to the growth of the global diabetes drugs market, and what are the new strategies adopted by them to retain a market share in the industry?
  • What is the competitive strength of the key players in the diabetes drugs market?
  • What new products are going to be approved or launched in the coming years which may have a huge impact on the market?
  • What insights are derived through the analysis of key players on the following parameters: company overview, financial performance, product portfolio, geographical presence, key highlights, and strategies?

Latest Reports

Global Oncology Precision Medicine Market

Global Oncology Precision Medicine Market, By Ecosystem (Applied Sciences (Genomics, Pharmacogenomics and Other Applied Sciences), Precision Diagnostics (Molecular Diagnostics …

Read More

Global Small Molecule Drug Discovery Market

Global Small Molecule Drug Discovery Market, By Therapeutic Type (Central Nervous System (CNS), Cardiovascular, Oncology, Metabolic Disorders, Gastrointestinal, Orthopedics, …

Read More

Global Diabetes Drugs Market

Global Diabetes Drugs Market, By Diabetes Type (Type-1 & Type-2), By Drug (Oral Anti-Diabetic Drugs (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine …

Read More

Global Bipolar Disorder Treatment Market

Global Bipolar Disorder Treatment Market, By Drug Type (Antipsychotic, Antidepressant, Anticonvulsants, Antianxiety, Mood Stabilizers, Others), By Bipolar Disorder Type …

Read More

Global Cytotoxic Drugs Contract Manufacturing Market

Global Cytotoxic Drugs Contract Manufacturing Market, By Product Type (Oral, Intravenous), By Form (Liquid, Solid), By Production Scale (Laboratory …

Read More

India Acetazolamide Market

India Acetazolamide Market, By Formulation (Tablets, Capsules, and Injection), By Application (Glaucoma, Epilepsy, Drug-induced Edema, Altitude …

Read More

India Diclofenac Market

India Diclofenac Market, By Indication (Osteoarthritis, Ankylosing Spondylitis, Dysmenorrhea, Rheumatoid Arthritis, Migraine, Pain, and Others), By Route of Administration …

Read More

Global Polycystic Ovarian Syndrome (PCOS) Treatment Market

Global Polycystic Ovarian Syndrome (PCOS) Treatment Market, By Drug Class (Contraceptives & Antiandrogens (Provera, Yasminell, Clomid, Aldactone, Diane 35, …

Read More
Validation error occured. Please enter the fields and submit it again.